This is a working overview of peptide research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-30. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
== Available forms == The abuse-deterring effects of atropine when used as an adulterant are reasonably effective in reducing the combination's potential for recreational use. It combines the mechanisms of naloxone and paracetamol (the two more commonly used abuse-deterring agents) by increasing the likelihood of the overdose resulting in harmful and/or fatal sequelae (as does paracetamol), in addition to reliably producing unpleasant side-effects which "spoil" the opioid euphoria and discourage abusers from overdosing again following their initial experience (as does naloxone). This does not deter the use of single doses of difenoxin to potentiate another opiate, the anticholingeric activity of a single tablet is actually likely to increase the pleasurable effects of opioid use in a manner similar to combining one or more opioids with orphenadrine.
The dosage of succinylcholine is patient-specific and determined based on total body weight and physical condition, thus extensive patient assessment and evaluation are required for accurate calculation. The current recommended dose of succinylcholine indicated for tracheal intubation by the FDA for adults is 1.0-1.5 mg/kg. Whereas, studies have shown that low-dose succinylcholine (0.45 mg/kg) is suitable for optimal intubation conditions in ASA 3 and 4 emergency non-prepared-patients (A patient with severe systemic disease that is a constant threat to life). This dosage can generate profound blockage within 60 seconds (short onset), quicker than other neuromuscular drugs currently available. Where neuromuscular blockage begins to recover within 3 minutes and is completely recovered within 15 minutes. Estimating the dose higher for intubation is preferred over underdosing, as reasonably higher dose produces similar paralysis with little to no known dose associated risks. Whereas under-dosing has shown inadequate paralysis, creating difficulties whilst performing intubation or other operative procedures.
The United States House of Representatives votes 220–211 to pass the $1.9 trillion American Rescue Plan Act of 2021. The stimulus bill was signed into law by President Biden the next day. Cannabis in South Dakota Attorneys defending Amendment A, which would have legalized cannabis in the state on July 1 before being struck down by a lower court judge, submit their arguments to the South Dakota Supreme Court. An attempt to delay the effective date of South Dakota's medical cannabis law from July 2021 until January 2022 fails due to disagreements between the South Dakota House and Senate on the proposed legislation. March 11 COVID-19 pandemic Minnesota reports its first case of the South African 501.V2 variant of COVID-19. The patient is a person from the Twin Cities area who became ill on January 24 and tested positive on January 29. Washington reports its first case of the Lineage P.1 variant of SARS-CoV-2, which originated in Brazil. The patient is a person from the King County. South Dakota reports its first case of the Lineage B.1.1.7 variant of SARS-CoV-2, which originated in the United Kingdom. March 12 The family of George Floyd, the man murdered while in police custody last May, sparking nationwide (and later worldwide) protests against police brutality and systemic racism, settles their lawsuit against the city of Minneapolis for $27 million. COVID-19 pandemic COVID-19 vaccination in the United States: The U.S. surpasses 100 million COVID-19 vaccine doses administered. Arizona reports its first three cases of the Lineage P.1 variant, which originated in Brazil.
Sources: en.wikipedia.org
The needle may cut small pieces of rubber from the septum as it injects sample through it. These can block the needle and prevent the syringe filling the next time it is used. It may not be obvious that this has happened. A fraction of the sample may get trapped in the rubber, to be released during subsequent injections. This can give rise to ghost peaks in the chromatogram. There may be selective loss of the more volatile components of the sample by evaporation from the tip of the needle.
In May 2021, Mesa Grill in Caesars Palace was converted to an Italian restaurant called Amalfi by Bobby Flay. He also updated the menu and changed the name of his Las Vegas Bobby's Burger Palace to Bobby's Burgers. He now has four locations of Bobby's Burgers in Caesars Palace Las Vegas, Paris Hotel Las Vegas, Harrah's Las Vegas, and Yankee Stadium in New York City. As of September 2019, Flay has an estimated net worth of $30 million.
== Awards == Royal Society of Western Australia, University Medal for outstanding student in natural and earth sciences (2003) Society of Environmental Toxicology and Chemistry, Best Platform Presentation by a student (2008) FNR ATTRACT Fellowship for the development of new methods to identify unknown chemicals (2018) The Analytical Scientist, Top 40 under 40 Power List (2018) The Analytical Scientist Power List, "Planet Protectors" field (2024)
The Hong Kong Rugby Football Union was founded in 1953. Rugby is long established, partly as a result of its being a British colony. Hong Kong Sevens is held annually in Hong Kong and is considered the premier tournament on the World Rugby Sevens Series competition. Hong Kong national rugby union team is ranked 23rd in the world with a peak rating of 21st (2018–2022). Hong Kong is one of the best teams in Asia and has finished first place in the Asia Rugby Championship in 2018, 2019, 2022, 2023, 2024, and 2025. They qualified for the 2027 Rugby World Cup for the first time by winning the 2025 Asia Rugby Championship. The Hong Kong national rugby sevens team is widely regarded as the best rugby sevens team in Asia and a regular participant in the Rugby World Cup Sevens. Hong Kong has won the Asian Sevens Series a record 8 times and the Asian Games 2 times.
Sources: en.wikipedia.org
Cell breakdown products cannot be reused, and are therefore degraded. This gives rise to increased uric acid, a purine breakdown product. The de novo pathway is stimulated due to an excess of PRPP (5-phospho-D-ribosyl-1-pyrophosphate or simply phosphoribosyl-pyrophosphate). It was previously unclear whether the neurological abnormalities in LNS were due to uric acid neurotoxicity or to a relative shortage in "new" purine nucleotides during essential synthesis steps. Genetic mutations affecting the enzymes of the de novo synthesis pathway may possibly contribute to the disease, although these are rare or unknown. Uric acid has been suggested as a possible cause of neurotoxicity but this is unproven. Importantly, evidence suggests that one or more lesions in striatal dopaminergic pathways may be central to the neurological deficits, especially the choreoathetoid dyskinesia and self-mutilation. 6-hydroxydopamine toxicity in rodents may be a useful animal model for the syndrome, although this is not proven. However, the link between dopamine and purine synthesis is a nucleotide called guanosine triphosphate or 'GTP'. The first step of dopamine synthesis is GTP cyclohydrolase, and significantly a deficiency of this step produces a syndrome that has a neuropathology similar to LNS. Thus a lack of HGPRT may produce a nucleotide deficiency (specifically: GTP deficiency) disorder, resulting in dopamine deficiency. Another animal model for LNS has been proposed to arise from oxidative damage, caused by the hyperuricemia accompanying LNS.
==== Legion number and title (cognomen) ==== The numbering of the legions is confusing, since several legions shared the same number with others. Augustus numbered the legions he founded himself from I, but also inherited numbers from his predecessors. Each emperor normally numbered the legions he raised himself starting from I. However, even this practice was not consistently followed. For example, Vespasian kept the same numbers as before for legions he raised from disbanded units. Trajan's first legion was numbered XXX because there were 29 other legions in existence at the time it was raised; but the second Trajanic legion was given the sequential number II. XVII, XVIII and XIX, the numbers of the legions annihilated in the Teutoburg Forest, were never used again. (These three legions are without titles, suggesting that in disgrace their titles may have been deliberately forgotten or left unmentioned.) As a result of this somewhat chaotic evolution, the legion's title became necessary to distinguish between legions with the same number. Legions often carried several titles, awarded after successive campaigns, normally by the ruling emperor e.g. XII Fulminata was also awarded: paterna (fatherly), victrix (victorious), antiqua (venerable), certa constans (reliable, steadfast) and Galliena (Gallienus '). Pia fidelis (loyal and faithful), fidelis constans and others were titles awarded to several legions, sometimes several times to the same legion. Only the most established, commonly used titles are displayed on this table. The geographical titles indicate
==== England ==== Potassium alum was imported into England mainly from the Middle East, and, from the late 15th century onwards, the Papal States for hundreds of years. Its use there was as a dye-fixer (mordant) for wool (which was one of England's primary industries, the value of which increased significantly if dyed). These sources were unreliable, however, and there was a push to develop a source in England especially as imports from the Papal States ceased following the excommunication of Henry VIII. With state financing, attempts were made throughout the 16th century, but without success until the early 17th century. An industry was founded in Yorkshire to process the shale, which contained the key ingredient, aluminium sulfate, and made an important contribution to the Industrial Revolution. One of the oldest historic sites for the production of alum from shale and human urine are the Peak alum works in Ravenscar, North Yorkshire. By the 18th century, the landscape of northeast Yorkshire had been devastated by this process, which involved constructing 100-foot (30 m) stacks of burning shale and fuelling them with firewood continuously for months. The rest of the production process consisted of quarrying, extraction, steeping of shale ash with seaweed in urine, boiling, evaporating, crystallisation, milling and loading into sacks for export. Quarrying ate into the cliffs of the area, the forests were felled for charcoal and the land polluted by sulfuric acid and ash.
=== Regulatory roles of ribosomal proteins === Recent genetic evidence has been interpreted to suggest that individual proteins of the eukaryotic ribosome directly contribute to the regulation of translation. However, this interpretation is controversial and some researchers have proposed that genetic changes to ribosomal protein genes indirectly affect overall ribosome numbers or ribosome biogenesis processes.
=== Technology === When considering food storage and preservation, the technologies of modified atmosphere and controlled atmosphere are widely used for the storage and packing of several types of foods. They offer several advantages such as delay of ripening and senescence of horticultural commodities, control of some biological processes such as rancidity, insects, bacteria and decay, among others. Controlled atmosphere (CA) storage refers to atmospheres that are different than normal air and strictly controlled at all times. This type of storage manipulates the CO2 and O2 levels within airtight stores of containers. Modified atmosphere (MA) storage refers to any atmosphere different from normal air, typically made by mixing CO2, O2, and N2.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.